Allergy Treatment Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The allergy treatment market covers prescription drugs, antihistamines, corticosteroids, decongestants, immunotherapy products, and diagnostic tools used by physicians and consumers to manage allergic conditions. Global revenue stood near $26 billion in 2025, with North America accounting for the largest share and the United States alone representing a market of more than $11 billion. Treatment demand is rising across both developed and emerging economies as allergy rates climb worldwide.

• •Estimated global market value of approximately $26.02 billion in 2025.
• •Forecast long-term growth at a compound annual rate of about 6.71%.
• •Allergic rhinitis alone represents a roughly $16 billion subset of the broader market.

The most consistent driver across regions is the rising prevalence of allergic disease, which is linked to air pollution, longer pollen seasons driven by climate change, urbanization, and shifting dietary patterns. Healthcare spending continues to grow in both developed and emerging markets, making advanced therapies such as sublingual and subcutaneous immunotherapy more accessible. Greater consumer awareness of self-medication options and the wider availability of OTC antihistamines are also accelerating treatment uptake.

• •Environmental factors such as pollution and extended pollen seasons are increasing allergy incidence.
• •Rising healthcare expenditure and insurance coverage support demand for advanced therapies.
• •Self-medication awareness is expanding the over-the-counter segment.

By treatment type, antihistamines and intranasal corticosteroids dominate revenue, while immunotherapy and biologics are the fastest-growing categories. By indication, allergic rhinitis leads in volume, followed by asthma, food allergies, and atopic dermatitis. North America holds the largest regional share, followed by Europe, while Asia-Pacific is the fastest-growing region as diagnosis rates and disposable incomes rise in countries such as China and India.

• •Antihistamines and corticosteroids remain the largest revenue segments by drug class.
• •Allergic rhinitis is the leading indication, with asthma and food allergies as growing segments.
• •Asia-Pacific is the fastest-growing regional market, while North America retains the largest share.

What are the recent trends and outlook?

The most important trend reshaping the market is the introduction of biologic drugs that target specific immune pathways, offering new options for patients with severe or treatment-resistant allergies. Digital health tools, including connected inhalers, tele-allergy consultations, and AI-supported diagnostics, are also expanding. Looking ahead, the market is expected to continue growing at a mid-to-high single-digit pace through the 2030s, supported by environmental and demographic trends that keep allergy rates on the rise.

• •Biologics and next-generation immunotherapies are driving premium growth within the market.
• •Digital and precision-medicine tools are improving diagnosis and treatment adherence.
• •Long-term demand is supported by structural factors including urbanization, pollution, and climate-related allergen exposure.